编号：2022-010 证券代码：301087 证券简称：可孚医疗 可孚医疗科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |--------------------|-----------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系活动类别 | 特定对象调研 \n□媒体采访 \n□新闻发布会 \n 现场参观 \n其他 | □分析师会议 \n 业绩说明会 \n □路演活动 \n 电话会议 | | 参与单位名称及人员 | | 新华资产张滢潭；中融基金杜伟；富国基金娄圣睿；上海证券黄卓、徐昕； | | 姓名 | | 兴业证券黄翰漾；国泰基金徐治彪；广州丹麓陆勤超、方文瀚；大成基金邹建； | | | | 东方阿尔法基金乔海英、程可；彤源投资谷 ...

编号：2022-009 证券代码：301087 证券简称：可孚医疗 可孚医疗科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-----------------------|-----------------------------------------------------------|--------------------------------------------------------------------------| | 投资者关系活动类别 | 特定对象调研 \n□媒体采访 \n□新闻发布会 \n 现场参观 \n其他 | □分析师会议 \n 业绩说明会 \n □路演活动 \n 电话会议 | | 参与单位名称及人员 | | 东吴证券汪澜；上海证券徐昕；万家基金王霄音、刘洋；诺德基金朱明睿； | | 姓名 | 国泰基金徐治彪、曾彪、姜英等。 | | | 时间 | 2022-5-6 | | | 地点 | 可孚医疗会议室 | | | 上市公司接待人员姓 名 | 董事/副总裁/董秘 | 薛小桥 | | | 1 | 、一季度应收和净利下滑原因是什么？ | | | | ...

编号：2022-011 证券代码：301087 证券简称：可孚医疗 可孚医疗科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-----------------------------|-------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

编号：2022-013 证券代码：301087 证券简称：可孚医疗 可孚医疗科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-------------------------|-----------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系活动类别 | 特定对象调研 \n□媒体采访 \n□新闻发布会 \n 现场参观 \n其他 | □分析师会议 \n 业绩说明会 \n □路演活动 \n 电话会议 | | 参与单位名称及人员 姓名 | 许睿。 | 宽潭资本蔡寒、朱一泓；华安证券李婵；建信基金马牧青、郑丁源；民生证券 | | 时间 | 2022-6-8 日至 | 2022-6-10 | | 地点 | 可孚医疗会议室 | | | 上市公司接待人员 ...

编号：2022-015 证券代码：301087 证券简称：可孚医疗 可孚医疗科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |----------------------------|---------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系活动类别 | ☑ 特定 ...

编号：2022-012 证券代码：301087 证券简称：可孚医疗 可孚医疗科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-----------------------------|-----------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

编号：2022-014 证券代码：301087 证券简称：可孚医疗 可孚医疗科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-----------------------------|-----------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系活动类别 | 特定对象调研 \n□媒体采访 \n□新闻发布会 \n 现场参观 \n其他 | □分析师会议 \n 业绩说明会 \n □路演活动 | | 参与单位名称及人员 | | 西部证券陆伏崴；建信养老谭翔宇；阳光资产王晓君；泰康资产陈璟；杭银理 | | 姓名 ...

编号：2022-016 证券代码：301087 证券简称：可孚医疗 可孚医疗科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |--------------------|-----------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系活动类别 | 特定对象调研 \n□媒体采访 \n□新闻发布会 \n 现场参观 \n其他 | □分析师会议 \n 业绩说明会 \n □路演活动 \n 电话会议 | | 参与单位名称及人员 | | 华安证券谭国超、李婵；禧弘基金杨莹；汐泰投资冯时、董函；中信期货魏巍； | | 姓名 | OrbiMed Stella | Xing、Claire Hu；东吴基金吴佳歆；东吴证券汪澜、向潇； | | | | 安信基 ...

编号：2022-017 证券代码：301087 证券简称：可孚医疗 可孚医疗科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-----------------------------|---------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Financial Performance - Total revenue for Q3 2022 was ¥582,011,013.21, a decrease of 2.71% compared to ¥598,205,940.70 in the same period last year[7] - Net profit attributable to shareholders for Q3 2022 was ¥37,247,040.91, down 58.06% from ¥88,805,230.20 year-on-year[7] - Net profit excluding non-recurring gains and losses for Q3 2022 was ¥19,876,937.73, a decline of 76.71% compared to ¥85,330,307.43 in the previous year[7] - Basic earnings per share for Q3 2022 was ¥0.18, a decrease of 68.42% from ¥0.74 in the same period last year[7] - The company reported a net profit margin of approximately 7.4% for the period[30] - The company's net profit for the current period is 169,070,013.38 CNY, a decrease from 304,702,433.63 CNY in the previous period, representing a decline of approximately 44.5%[33] - Operating profit for the current period is 192,947,569.00 CNY, down from 366,589,272.10 CNY in the previous period, indicating a decrease of about 47.4%[33] - The company reported a total profit of 190,455,728.34 CNY, down from 365,130,522.31 CNY in the previous period, representing a decrease of about 47.9%[33] Cash Flow and Liquidity - Cash flow from operating activities for the year-to-date period was ¥50,032,768.56, down 47.57% from ¥95,428,344.89[7] - The net cash flow from operating activities decreased by 47.57% to ¥50,032,768.56 compared to ¥95,428,344.89 in the same period last year, primarily due to increased inventory and prepayments to suppliers[17] - Cash and cash equivalents decreased to RMB 1,291,211,063.62 from RMB 1,989,232,177.59, reflecting a decline of 35.1%[24] - The ending balance of cash and cash equivalents is 1,202,548,446.30 CNY, down from 71,280,969.57 CNY in the previous period, indicating a decrease in liquidity[40] Assets and Liabilities - Total assets attributable to shareholders at the end of the reporting period were ¥5,807,122,186.75, an increase of 4.30% compared to the previous year[7] - Total assets reached RMB 6,056,899,703.90, compared to RMB 5,807,122,186.75 at the beginning of the year, indicating a growth of 4.3%[29] - Short-term borrowings increased by 346.46% to ¥370,896,799.21, primarily due to increased internal bill discounting[13] - Long-term payables increased by 134.63% to ¥11,731,609.50, primarily due to new acquisition-related payment obligations[16] - The company experienced a 1009.94% increase in other current liabilities, totaling ¥63,135.31, mainly due to increased tax liabilities from domestic sales contracts[16] - Non-current liabilities totaled RMB 177,570,813.55, an increase from RMB 159,391,635.36[29] Expenses - Sales expenses increased by 43.19% to ¥434,162,579.06, mainly due to the consolidation of Acorn Trading and Jiri Medical, along with increased marketing investments and a significant rise in sales personnel[16] - Research and development expenses rose by 52.55% to ¥70,272,006.27, attributed to the addition of 33 new R&D projects and an increase in R&D personnel[16] Investments and Acquisitions - The company reported a significant increase in goodwill to ¥228,892,834.74, up 371.06% due to the acquisition of Acorn Trading[13] - The company raised 1,302,591,966.13 CNY through borrowings, compared to 88,762,417.78 CNY in the previous period, marking a substantial increase in financing activities[40] - The company reported a net cash outflow from investing activities of -712,018,224.01 CNY, compared to -290,431,353.48 CNY in the previous period, indicating a significant increase in cash outflow[40] Government Support - The company received government subsidies amounting to ¥9,903,531.52 during the reporting period[8] Future Outlook - The company plans to expand its market presence and invest in new product development to drive future growth[28]